

Resource Summary Report

Generated by [dkNET](#) on Aug 31, 2026

WiDr

RRID:CVCL_2760

Type: Cell Line

Proper Citation

RRID:CVCL_2760

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2760

Proper Citation: RRID:CVCL_2760

Description: Cell line WiDr is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Colon adenocarcinoma

Defining Citation: [PMID:90012](#), [PMID:327080](#), [PMID:833871](#), [PMID:1389533](#), [PMID:1657424](#), [PMID:3335022](#), [PMID:3472642](#), [PMID:3518877](#), [PMID:4203458](#), [PMID:7118132](#), [PMID:7874267](#), [PMID:8464898](#), [PMID:9290701](#), [PMID:9488600](#), [PMID:10674020](#), [PMID:10956384](#), [PMID:11414198](#), [PMID:16854228](#), [PMID:20143388](#), [PMID:20215515](#), [PMID:20570890](#), [PMID:23932154](#), [PMID:24042735](#), [PMID:25485619](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:26537799](#), [PMID:26589293](#), [PMID:28683746](#)

Comments: Population: Caucasian., Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=3472642; PubMed=20143388). Originally thought to originate from a 78 year old female patient with a primary adenocarcinoma of the rectosigmoid colon..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: WiDr

Synonyms: WiDR, WIDR, WiDr/S, WiDr-TC, WiDrTC, LED-WiDr, Led-WiDr

Cross References: BTO:BTO_0001483, CLO:CLO_0009600, EFO:EFO_0002389, CLDB:cl4715, CLDB:cl4988, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ATCC:CCL-218, BCRC:60157, BioSample:SAMN03151797, cancercellines:CVCL_2760,

Cell_Model_Passport:SIDM00152, ChEMBL-Cells:CHEMBL3307674, ChEMBL-Targets:CHEMBL614647, CLS:300377, ColonAtlas:WIDR, Cosmic:738928, Cosmic:887216, Cosmic:897740, Cosmic:905002, Cosmic:1066213, Cosmic:1122336, Cosmic:1132695, Cosmic:1184091, Cosmic:1187326, Cosmic:1218881, Cosmic:1466826, Cosmic:1479615, Cosmic:1609498, Cosmic:1676736, Cosmic:2651871, Cosmic:2664048, Cosmic:2668255, Cosmic:2760078, ECACC:85111501, EGA:EGAS00001000610, EGA:EGAS00001002554, FCS-free:180-2-342-3-16-3, GEO:GSM784020, GEO:GSM827327, GEO:GSM1006242, GEO:GSM1006243, GEO:GSM1006244, GEO:GSM1374987, GEO:GSM1374988, GEO:GSM1448091, GEO:GSM2550022, IARC_TP53:21, ICLC:HTL00003, IGRhCellID:WIDR, JCRB:IFO50043, JCRB:JCRB0224, KCLB:10218, LINCS_HMS:50049, LINCS_LDP:LCL-1169, MetaboLights:MTBLS227, NCI-DTP:WIDR, PharmacDB:WIDR_1660_2019, Progenetix:CVCL_2760, PubChem_Cell_line:CVCL_2760, RCB:RCB1908, TKG:TKG 0513, TKG:TKG 0516, Wikidata:Q54994056

ID: CVCL_2760

Hierarchy: cvcl_0320

Record Creation Time: 20220427T221720+0000

Record Last Update: 20260830T000320+0000

Ratings and Alerts

No rating or validation information has been found for WiDr.

Warning: Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=3472642; PubMed=20143388). Originally thought to originate from a 78 year old female patient with a primary adenocarcinoma of the rectosigmoid colon.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00103.

Population: Caucasian., Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=3472642; PubMed=20143388). Originally thought to originate from a 78 year old female patient with a primary adenocarcinoma of the rectosigmoid colon..

Warning: Discontinued: RCB; RCB1908

Population: Caucasian., Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=3472642; PubMed=20143388). Originally thought to originate from a 78 year old female patient with a primary adenocarcinoma of the rectosigmoid colon..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Gonçalves TJ, et al. (2026) Preventive Effect of Butyrate in Colon Cancer Cell Metabolism. International journal of molecular sciences, 27(8).

Tak E, et al. (2025) Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer. Cancer immunology, immunotherapy : CII, 74(5), 154.

Champagne J, et al. (2025) Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. Immunity, 58(1), 247.

Kanoda R, et al. (2025) Downregulation of cGAS/STING expression in tumor cells by cancer-associated fibroblasts in colorectal cancer. Scientific reports, 15(1), 19234.

Biederstädt A, et al. (2025) Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency. Cancer cell.

Sogari A, et al. (2024) Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells. Cell reports. Medicine, 5(2), 101376.

Iwata M, et al. (2024) Reduced chemokine C-C motif ligand 1 expression may negatively regulate colorectal cancer progression at liver metastatic sites. Journal of cellular and molecular medicine, 28(7), e18193.

Shanley M, et al. (2024) Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer cell, 42(8), 1450.

Hashimoto N, et al. (2024) Bidirectional signals generated by Siglec-7 and its crucial ligand tri-sialylated T to escape of cancer cells from immune surveillance. iScience, 27(11), 111139.

Maione F, et al. (2024) Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models. Molecular oncology.

Stanland LJ, et al. (2023) CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer. Molecular cancer research : MCR, 21(11), 1148.

Chu YD, et al. (2023) Aldolase B-driven lactagenesis and CEACAM6 activation promote cell renewal and chemoresistance in colorectal cancer through the Warburg effect. Cell death & disease, 14(10), 660.

Satow R, et al. (2022) Downregulation of protein kinase C gamma reduces epithelial property and enhances malignant phenotypes in colorectal cancer cells. iScience, 25(12), 105501.

Uchihara Y, et al. (2022) DNA damage promotes HLA class I presentation by stimulating a pioneer round of translation-associated antigen production. Molecular cell, 82(14), 2557.

Moy RH, et al. (2022) Functional genetic screen identifies ITPR3/calcium/RELB axis as a driver of colorectal cancer metastatic liver colonization. Developmental cell, 57(9), 1146.

Gneo L, et al. (2022) TGF- β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer. *Cancer immunology, immunotherapy* : CII, 71(7), 1583.

Champagne J, et al. (2021) Oncogene-dependent sloppiness in mRNA translation. *Molecular cell*, 81(22), 4709.

Vitiello PP, et al. (2021) Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. *Journal of experimental & clinical cancer research* : CR, 40(1), 15.

Or CR, et al. (2020) Obatoclax, a Pan-BCL-2 Inhibitor, Downregulates Survivin to Induce Apoptosis in Human Colorectal Carcinoma Cells Via Suppressing WNT/ β -catenin Signaling. *International journal of molecular sciences*, 21(5).

Kim N, et al. (2020) Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab. *International journal of cancer*, 146(8), 2194.